Clinical Cancer Research Meeting Calendar Advances in Breast Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zonder, J. A.
Right arrow Articles by Philip, P. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zonder, J. A.
Right arrow Articles by Philip, P. A.
Clinical Cancer Research Vol. 7, 38-42, January 2001
© 2001 American Association for Cancer Research

Clinical Trials

A Phase II Trial of Bryostatin 1 in the Treatment of Metastatic Colorectal Cancer1

Jeffrey A. Zonder, Anthony F. Shields, Mark Zalupski, Ruth Chaplen, Lance K. Heilbrun, Patricia Arlauskas and Philip A. Philip2

Division of Hematology and Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan 48201


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 PATIENTS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Current chemotherapy for patients with advanced colorectal cancer is relatively ineffective and may be associated with significant toxicity. Bryostatin 1 (bryo 1) influences cell proliferation, intracellular metabolism and signaling, differentiation, and apoptosis in human cancer cell lines via modulation of protein kinase C (PKC) activity. This trial investigates the efficacy and toxicity of bryo 1 as a novel therapeutic agent for patients with advanced colorectal cancer who have had previous 5-fluorouracil therapy. The primary end point was tumor response to bryo 1. Toxicity was also assessed. Twenty-eight patients with advanced colorectal cancer were enrolled. The mean age was 59 years (range, 38–76), with 16 men and 12 women, and good minority representation (11 African-Americans). The first 10 patients initially received 25 µg/m2 of bryo 1 weekly as a 24-h infusion for 3 weeks of every 4-week cycle, with dose escalation to 35 µg/m2 starting with the second cycle. The remaining patients were started at 35 µg/m2 and escalated to 40 µg/m2, if toxicity was minimal. Twenty-five patients were evaluable for objective tumor response, and complete data on toxicity were collected on 26 patients. No partial or complete tumor responses were observed. All 25 patients had disease progression within four cycles. Myalgia was the most common toxicity. Myelosuppression was not seen. bryo 1 as a weekly 24-h continuous infusion lacks single-agent antitumor activity in advanced colorectal cancer. Toxicity differs from that of traditional chemotherapeutic drugs.


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
PATIENTS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Approximately 15% of patients with colorectal cancer have metastatic disease at presentation. Additionally, nearly two-thirds of patients with resected disease involving locoregional lymph nodes will recur within 5 years of initial treatment (1) . Median survival for patients with untreated metastatic colorectal cancer is 6–8 months.

The most extensively studied drug in the treatment of metastatic colorectal cancer is 5-FU.3 Median survival for patients treated with 5-FU is ~11 months, with a 23% response rate (2) . Recently, additional drugs for colorectal cancer have been introduced. Irinotecan has been approved for the treatment of patients who have failed 5-FU therapy. This is largely on the basis of two studies, one evaluating irinotecan versus best supportive care in 5-FU-refractory metastatic colorectal cancer (3) and another comparing irinotecan to continuous infusion 5-FU (4) . One-year survival was in the 40% range in the irinotecan arms of these trials. Grade 3–4 diarrhea and neutropenia was relatively frequent in both studies. Oxaliplatin shows promise (5 , 6) , particularly when combined with 5-FU (7) or irinotecan (8) , but at the time of this writing, oxaliplatin is not licensed for use in the United States. Taken together, the current data indicate that more effective, less toxic therapy for metastatic colorectal cancer is needed.

PKC is a family of closely related, lipid-dependent and diacylglycerol-activated isoenzymes with an important role in intracellular signaling pathways (9, 10, 11, 12) . PKC may have a role in normal colonic cell homeostasis and neoplastic transformation (13) . Modulation of PKC affects in vitro differentiation of colon cancer cells (14 , 15) . 12-O-Tetradecanoylphorbol 13-O-acetate, a tumor promoter that modulates PKC activity, induces colon cancer cell terminal differentiation in several cell lines (15, 16, 17) . PKC activation is implicated in tumor promotion in colonic epithelial cells by endogenous and dietary factors such as bile acids, free fatty acids, and diacylglycerol (18) .

bryo 1, a macrocyclic lactone derived from the marine invertebrate Bugula neritina (19 , 20) , has a panoply of PKC-mediated biological effects. bryo 1 influences hematopoiesis (21 , 22) , lymphocyte function (23) , platelet activation (24) , and cell differentiation (15 , 25, 26, 27) . bryo 1 also has direct cytotoxic effects in some human cancer cell lines (28) and modulates the in vitro cytotoxic effects of several chemotherapeutic agents, both in hematological (29) and nonhematological (30, 31, 32, 33, 34) tumors. Phase I studies demonstrate that bryo 1 has minimal toxicity; myalgia is usually dose-limiting, and myelosuppression is observed rarely (35, 36, 37, 38, 39) .

This Phase II study was designed to evaluate the efficacy of bryo 1 as a novel therapeutic agent in the treatment of metastatic colorectal cancer when administered as a weekly 24-h continuous infusion i.v. Additionally, information regarding toxicity of this drug was obtained.


   PATIENTS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 PATIENTS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Study Design.
This was a single-institution, Phase II clinical trial. All patients were treated with bryo 1, with initial dosing and planned dose escalation as described below. A complete response was defined as the disappearance of all measurable and evaluable tumor without the appearance of any new lesions on two successive measurements separated by 8 weeks. Partial response was defined as reduction of the sum of the cross-sectional areas of measurable lesions by >50% on two successive measurements. Stable disease was characterized by shrinkage of <50% or growth of <25%, whereas progressive disease was defined as a >25% increase in the sum of the cross-sectional areas of measurable lesions. The study had a 0.79 power to distinguish regions of (true, unknown) response rates of 5% or less versus 20% or more.

Patient Eligibility.
Patients with measurable, histologically proven, metastatic colorectal cancer were eligible for this trial. Prior treatment with up to one 5-FU-based regimen was acceptable, as was prior radiation therapy. Patients treated previously with other investigational agents within 1 month of study entry were excluded. All patients had to have a Southwest Oncology Group scale performance status of 0–2. Adequate bone marrow function (absolute neutrophil count, >=1500/cmm; platelet count, >=100,000/cmm), liver function (total bilirubin, <=1.5 x institutional upper limit of normal, aspartate aminotransferase <=2.5 x institutional upper limit of normal) and renal function (serum creatinine <=1.5 mg/dl) were required. Patients with active infections, other serious systemic conditions, or an active second primary malignancy (other than in situ carcinoma of the cervix or adequately treated basal cell carcinoma of the skin) were excluded, as were patients with uncontrolled brain metastases. Patients who were lactating or pregnant were not eligible. Entrants with reproductive potential were required to use effective contraception. The study was approved by the Human Investigation Committee at Wayne State University. All patients provided signed informed consent.

Treatment Scheme.
Patients were treated with bryo 1 via central venous access in 4-week cycles (three consecutive weekly 24-h infusions followed by a week break). bryo 1 was kindly supplied by the National Cancer Institute, Cancer Therapy Evaluation Program. Initially, the starting dose of bryo 1 was 25 µg/m2 with planned dose escalation to 35 µg/m2 if there was minimal toxicity. Because each of the first 10 consecutive patients enrolled met criteria for dose escalation, the trial was amended, and all remaining patients were started at 35 µg/m2, with dose escalation to 40 µg/m2 if no significant toxicity was observed in the initial cycle. This scheme is summarized in Table 1Citation . Treatment cycles were repeated until disease progression or unacceptable toxicity occurred. Treatment was delayed for any grade 2 or higher hematological or nonhematological toxicity until recovery. Any grade 3 or 4 toxicity (except alopecia, nausea, or vomiting) prompted a dosage reduction of 5 µg/m2 for subsequent cycles.


View this table:
[in this window]
[in a new window]

  		Table 1 Treatment scheme for 28 patients with advanced colorectal cancer treated with bryostatin 1

 
Trial Procedures.
Initial evaluation of patients included a complete history and physical examination, performance status assessment, a complete blood count, and a multiphasic chemistry panel. Additionally, a computed tomographic scan of the abdomen and a computed tomographic scan or X-ray of the chest within 4 weeks prior to starting therapy was required.

Before each cycle, the complete blood count and multiphasic chemistry panel, performance status, and a toxicity profile were evaluated. Tumor measurements, if possible, were documented; if the tumor was only assessable radiographically, this was done after cycles 2 and 4. Toxicity assessment used the National Cancer Institute common toxicity criteria (http://ctep.info.nih.gov).


   RESULTS
Top
 ABSTRACT
 INTRODUCTION
 PATIENTS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Patients.
A total of 28 patients were enrolled. Table 2Citation provides a summary of patient characteristics. The mean age was 59 years (range, 38–76). There were 16 men and 12 women. Eleven of the patients were African-American, with the other 17 being Caucasian. Eighteen of the patients had colon primaries, and the other 10 had rectal tumors. The mean time from initial diagnosis to treatment with bryo 1 was 20 months (range, 6–55). 5-FU had been received as adjuvant therapy for 14 of the patients and for metastatic disease in the other 14. There was a median of two sites of metastases/patient, the most frequent being liver and lung.


View this table:
[in this window]
[in a new window]

  		Table 2 Characteristics of 28 patients treated with bryostatin 1 for metastatic colorectal cancer

 
Efficacy.
Twenty-five of 28 enrolled patients were evaluable for objective tumor response. Three patients were not assessable for tumor response, because they voluntarily withdrew from the study after fewer than two cycles of bryo 1. Of the remaining twenty-five patients, 21 had progressive disease after two cycles of bryo 1, and the other four patients had disease progression by completion of four cycles. There were no complete or partial responses observed (response rate, 0 of 25, 0%; 95% confidence interval, 0.00–0.14). The median overall survival of the 28 patients entered into this study as determined by the Kaplan-Meier method was 6.1 months (95% confidence interval, 5.2–11.2 months; Fig. 1Citation ). Of the 28 enrolled patients, 22 have expired, yielding a censoring rate of only 6 of 28 (21%).



View larger version (12K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. Survival curve for 28 patients with advanced colorectal cancer treated with bryo 1. Dashed lines are the 95% confidence limits for the survival rate at a specific time point.

 
Toxicity.
Twenty-six patients were evaluable for toxicity. Two patients, one of whom received less than one complete cycle of bryo 1 and another who withdrew prior to receiving any bryo 1, were not considered eligible for toxicity evaluation. Table 3Citation shows the frequency and severity of side effects observed. Two patients required hospitalization, one for grade III nausea, vomiting, and dehydration likely related to a bowel obstruction, and a second for Gram-negative sepsis and pneumonia (without neutropenia). No myelosuppression was noted. Myalgia was the most frequently observed side effect (13 of 26, 50% incidence rate; 95% confidence interval, 0.30–0.70), although in 11 of 13 patients, it was only grade I or II. The grade III/IV myalgia incidence rate was 2 of 26 (8%; 95% confidence interval, 0.02–0.26) at a dose level of 35 µg/m2 in each case. Fatigue, nausea, and vomiting were the next most common side effects of therapy, but these symptoms were generally mild. Other toxicities included elevated liver transaminases, diarrhea, sensory neuropathy, joint pain, mucositis, and depression. Two patients with preexisting diabetes experienced grade III hyperglycemic episodes during the study. In one case, the patient had an acute central venous catheter infection that was likely causative, and the other patient had multiple instances of hyperglycemia documented before and after the period he was being treated with bryo 1. Thus, it is unclear whether bryo 1 contributed to hyperglycemia in either case. Seven patients experienced no toxicity; 3 of 10 patients started at 25 µg/m2, and 4 of the remaining 18 started at 35 µg/m2.


View this table:
[in this window]
[in a new window]

  		Table 3 Worst grade of toxicity per patient among 26 colorectal cancer patients treated with bryostatin 1

 

   DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 PATIENTS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
In human colon cancer cell lines, PKC is involved in cell proliferation (16 , 17 , 40 , 41) , intracellular metabolism (42) and signaling (43 , 44) , differentiation (15, 16, 17 , 45) , and apoptosis (46) . Using bryo 1 to modulate PKC activity or expression represents a novel treatment approach for colorectal malignancies. However, this Phase II study failed to demonstrate any clinically meaningful activity against advanced colorectal cancer by bryo 1 when used as a single agent. If bryo 1 has a true response rate of 20% (which we had hypothesized), then the probability of observing no responses among 25 patients is extremely low (P = 0.0038). Similarly disappointing results have been reported in Phase II trials of single-agent bryo 1 for melanoma (47, 48, 49) and in Phase I trials for bryo 1 in certain hematological malignancies (38) . The treatment schedule herein was based on a previous Phase I study (35) , but it is distinctly possible that a different treatment schedule might result in enhanced antitumor activity. Because no reliable assay to measure bryo 1 levels in biological fluids exists (50 , 51) , investigators have explored varying administration schedules of bryo 1 on the basis of theoretical, but unproven, grounds. The present study was limited to evaluation of tumor size. The answers to fundamental questions, such as whether bryo 1 influenced the PKC levels in the tumor cells in vivo or whether it affected cell differentiation or apoptosis, were not determined. Logistically, this type of data are difficult to collect, but future trials, if undertaken, might attempt to incorporate such an analysis.

The toxicity profile of bryo 1 at doses of 25–40 µg/m2 was quite favorable. Unlike previous clinical trials of bryo 1 (35, 36, 37, 38) , myalgia was rarely dose limiting. The reason for this difference is not entirely clear but may be related to dosing schedule. This study confirmed previous findings that myelosuppression is not a dose-limiting toxicity of bryo 1 in doses up to 40 µg/m2.

There is an emerging body of data showing that bryo 1 probably has little or no activity against nonhematological tumors when used as a single agent (36 , 47, 48, 49) . However, there is in vitro and animal xenograft data suggesting a potential role for bryo 1 as a response modifier to traditional cytotoxic agents (29 , 30 , 32 , 52, 53, 54) . Recent Phase I trials have demonstrated the feasibility of combining bryo 1 and these drugs (55 , 56) . With our growing understanding of the role of PKC in cellular growth and function, the in vitro data on synergy between bryo 1 and traditional chemotherapeutic drugs and the lack of myelosuppression or gastrointestinal toxicity observed in clinical trials of bryo 1, investigation of bryo 1 as a potential tumor response modifier to other drugs is clearly warranted.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was partially supported by NIH Cancer Center Support Grant CA-22453. Back

2 To whom requests for reprints should be addressed, at Division of Hematology and Oncology, Barbara Ann Karmanos Cancer Institute, 509 Hudson Building, 3990 John R. Street, Detroit, MI 48201. Phone: (313) 745-9155; Fax: (313) 993-0559; E-mail: philipp{at}karmanos.org Back

3 The abbreviations used are: 5-FU, 5-fluorouracil; PKC, protein kinase C; bryo 1, bryostatin 1. Back

Received 7/28/00; revised 10/17/00; accepted 10/17/00.


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 PATIENTS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Cohen A. M., Minsky B. D., Schilsky R. L. Cancer of the colon DeVita V. T. Hellman S. Rosenberg S. A. eds. . Cancer: Principles and Practice of Oncology, : 1144-1197, Lippincott-Raven Publishers Philadelphia 1997.
  2. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. J. Clin. Oncol., 10: 896–903, 1992.
  3. Cunningham D., Pyrhonen S., James R. D., Punt C. J., Hickish T. F., Heikkila R., Johannesen T. B., Starkhammar H., Topham C. A., Awad L., Jacques C., Herait P. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet, 352: 1413-1418, 1998.[CrossRef][Medline]
  4. Rougier P., Van Cutsem E., Bajetta E., Niederle N., Possinger K., Labianca R., Navarro M., Morant R., Bleiberg H., Wils J., Awad L., Herait P., Jacques C. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet, 352: 1407-1412, 1998.[CrossRef][Medline]
  5. Diaz-Rubio E., Sastre J., Zaniboni A., Labianca R., Cortes-Funes H., de Braud F., Boni C., Benavides M., Dallavalle G., Homercin M. Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a Phase II multicentric study. Ann. Oncol., 9: 105-108, 1998.[Abstract/Free Full Text]
  6. Becouarn Y., Ychou M., Ducreux M., Borel C., Bertheault-Cvitkovic F., Seitz J. F., Nasca S., Nguyen T. D., Paillot B., Raoul J. L., Daffour J., Fandi A., Dupont-Andre G., Rougier P. Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers. J. Clin. Oncol., 16: 2739-2744, 1998.[Abstract]
  7. Levi F., Zidani R., Misset J. L. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy. Lancet, 350: 681-686, 1997.[CrossRef][Medline]
  8. Scheithauer W., Kornek G. V., Raderer M., Valencak J., Weinlander G., Hejna M., Haider K., Kwasny W., Depisch D. Combined irinotecan and oxaliplatin plus granulocyte colony-stimulating factor in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer. J. Clin. Oncol., 17: 902-906, 1999.[Abstract/Free Full Text]
  9. Nishizuka Y. The role of protein kinase C in cell surface signal transduction and tumor promotion. Nature (Lond.), 308: 693-698, 1984.[CrossRef][Medline]
  10. Stabel S., Parker P. J. Protein kinase C. Pharmacol. Therapeut., 51: 71-95, 1991.[CrossRef][Medline]
  11. Azzi A., Boscoboinik D., Hensey C. The protein kinase C family. Eur. J. Biochem., 208: 547-557, 1992.[Medline]
  12. Philip P. A., Harris A. L. Potential for protein kinase C inhibitors in cancer therapy Muggia F. M. eds. . Concepts, Mechanisms, and New Targets for Chemotherapy, : 3-27, Kluwer Academic Publishers Boston 1995.
  13. Weller S. G., Klein I. K., Penington R. C., Karnes W. E., Jr. Distinct protein kinase C isozymes signal mitogenesis and apoptosis in human colon cancer cells. Gastroenterology, 117: 848-857, 1999.[CrossRef][Medline]
  14. McBain J. A., Pettit G. R., Mueller G. C. Bryostatin 1 antagonizes the terminal differentiating action of 12-O-tetradecanoylphorbol-13-acetate in a human colon cancer cell. Carcinogenesis (Lond.), 9: 123-129, 1988.[Abstract/Free Full Text]
  15. McBain J. A., Pettit G. R., Mueller G. C. Phorbol esters activate proteoglycan metabolism in human colon cancer cells en route to terminal differentiation. Cell Growth Differ., 1: 281-291, 1990.[Abstract]
  16. Goldstein D. R., Cacace A. M., Weinstein I. B. Overexpression of protein kinase C ß1 in the SW480 colon cancer cell line causes growth suppression. Carcinogenesis (Lond.), 16: 1121-1126, 1995.[Abstract/Free Full Text]
  17. Choi P. M., Tchou-Wong K. M., Weinstein I. B. Overexpression of protein kinase C in HT29 colon cancer cells causes growth inhibition and tumor suppression. Mol. Cell. Biol., 10: 4650-4657, 1990.[Abstract/Free Full Text]
  18. Chapkin R. S., Jiang Y. H., Davidson L. A., Lupton J. R. Modulation of intracellular second messengers by dietary fat during colonic tumor development. Adv. Exp. Med. Biol., 422: 85-96, 1997.[Medline]
  19. Pettit G. R., Herald C. L., Doubek D. L. Isolation and structure of bryostatin 1. J. Am. Chem. Soc., 104: 6846-6848, 1982.[CrossRef]
  20. Zonder J., Philip P. A. Pharmacology and clinical experience with bryostatin 1: a novel anticancer drug. Expert Opin. Investig. Drugs, 8: 2189-2199, 1999.[CrossRef][Medline]
  21. Li F., Grant S., Pettit G. R., McCrady C. W. Bryostatin 1 modulates the proliferation and lineage commitment of human myeloid progenitor cells exposed to recombinant interleukin-3 and recombinant granulocyte-macrophage colony-stimulating factor. Blood, 80: 2495-2502, 1992.[Abstract/Free Full Text]
  22. Sharkis S. J., Jones R. J., Bellis M. L., Demetri G. D., Griffin J. D., Civin C., May W. S. The action of bryostatin on normal human hematopoietic progenitors is mediated by accessory cell release of growth factors. Blood, 76: 716-720, 1990.[Abstract/Free Full Text]
  23. Eisemann K., Totola A., Jurcic K. Bryostatins 1, 2 and 5 activate human granulocytes and lymphocytes: in vitro and in vivo studies. Pharmaceut. Pharmacol. Lett., 1: 45-48, 1995.
  24. Berkow R. L., Schlabach L., Dodson R., Benjamin W. H., Jr., Pettit G. R., Rustagi P., Kraft A. S. In vivo administration of the anticancer agent bryostatin 1 activates platelets and neutrophils and modulates protein kinase C activity. Cancer Res., 53: 2810-2815, 1993.[Abstract/Free Full Text]
  25. Stone R. M., Sariban E., Pettit G. R., Kufe D. W. Bryostatin 1 activates protein kinase C and induces monocytic differentiation of HL-60 cells. Blood, 72: 208-213, 1988.[Abstract/Free Full Text]
  26. Kraft A. S., William F., Pettit G. R., Lilly M. B. Varied differentiation responses of human leukemias to bryostatin 1. Cancer Res., 49: 1287-1293, 1989.[Abstract/Free Full Text]
  27. Al-Katib A., Mohammad R. M., Mohamed A. N., Pettit G. R., Sensenbrenner L. L. Conversion of high grade lymphoma tumor cell line to intermediate grade with TPA and bryostatin 1 as determined by polypeptide analysis on 2D gel electrophoresis. Hematol. Oncol., 8: 81-89, 1990.[Medline]
  28. Kennedy M. J., Prestigiacomo L. J., Tyler G., May W. S., Davidson N. E. Differential effects of bryostatin 1 and phorbol ester on human breast cancer cell lines. Cancer Res., 52: 1278-1283, 1992.[Abstract/Free Full Text]
  29. Basu A., Evans R. W. Comparison of effects of growth factors and protein kinase C activators on cellular sensitivity to cis-diamminedichloroplatinum(II). Int. J. Cancer, 58: 587-591, 1994.[Medline]
  30. Mohammad R. M., Beck F. W., Katato K., Hamdy N., Wall N., Al-Katib A. Potentiation of 2-chlorodeoxyadenosine activity by bryostatin 1 in the resistant chronic lymphocytic leukemia cell line (WSU-CLL): association with increased ratios of dCK/5'-NT and Bax/Bcl-2. Biol. Chem., 379: 1253-1261, 1998.[Medline]
  31. Wang Z., Su Z. Z., Fisher P. B., Wang S., Van Tuyle G., Grant S. Evidence of a functional role for the cyclin-dependent kinase inhibitor p21(WAF1/CIP1/MDA6) in the reciprocal regulation of PKC activator-induced apoptosis and differentiation in human myelomonocytic leukemia cells. Exp. Cell Res., 244: 105-116, 1998.[CrossRef][Medline]
  32. Al-Katib A. M., Smith M. R., Kamanda W. S., Pettit G. R., Hamdan M., Mohamed A. N., Chelladurai B., Mohammad R. M. Bryostatin 1 down-regulates mdr1 and potentiates vincristine cytotoxicity in diffuse large cell lymphoma xenografts. Clin. Cancer Res., 4: 1305-1314, 1998.[Abstract]
  33. Chakrabarty S., Huang S. Modulation of chemosensitivity in human colon carcinoma cells by downregulating protein kinase C{alpha} expression. J. Exp. Ther. Oncol., 1: 218-221, 1996.[Medline]
  34. La Porta C. A., Dolfini E., Comolli R. Inhibition of protein kinase C-{alpha} isoform enhances the P-glycoprotein expression and the survival of LoVo human colon adenocarcinoma cells to doxorubicin exposure. Br. J. Cancer, 78: 1283-1287, 1998.[Medline]
  35. Philip P. A., Rea D., Thavasu P., Carmichael J., Stuart N. S., Rockett H., Talbot D. C., Ganesan T., Pettit G. R., Balkwill F., et al Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor {alpha} induction in vivo. The Cancer Research Campaign Phase I Committee. J. Natl. Cancer Inst., 85: 1812-1818, 1993.[Abstract/Free Full Text]
  36. Prendiville J., Crowther D., Thatcher N., Wall P. J., Fox B. W., Mcgown A., Testa N., Stern P., McDermott R., Potter M. A Phase I study of intravenous bryostatin 1 in patients with advanced cancer. Br. J. Cancer, 68: 418-424, 1993.[Medline]
  37. Jayson G. C., Crowther D., Prendiville J., McGown A. T., Scheid C., Stern P., Young R., Brenchley P., Chang J., Owens S. A Phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion. Br. J. Cancer, 72: 461-468, 1995.[Medline]
  38. Varterasian M. L., Mohammad R. M., Eilender D. S., Hulburd K., Rodriguez D. H., Pemberton P. A., Pluda J. M., Dan M. D., Pettit G. R., Chen B. D., Al-Katib A. M. Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. J. Clin. Oncol., 16: 56-62, 1998.[Abstract/Free Full Text]
  39. Grant S., Roberts J., Poplin E., Tombes M. B., Kyle B., Welch D., Carr M., Bear H. D. Phase Ib trial of bryostatin 1 in patients with refractory malignancies. Clin. Cancer Res., 4: 611-618, 1998.[Abstract]
  40. Matsubara N., Fuchimoto S., Orita K. Differing roles of protein kinase C on the antiproliferative effects of tumor necrosis factor {alpha} and ß on LoVo cells. Pathobiology, 58: 168-171, 1990.[CrossRef][Medline]
  41. Sauma S., Yan Z., Ohno S., Friedman E. Protein kinase C ß1 and protein kinase C ß2 activate p57 mitogen-activated protein kinase and block differentiation in colon carcinoma cells. Cell Growth Differ., 7: 587-594, 1996.[Abstract]
  42. Ostrowski J., Szczepiorkowski Z., Trzeciak L., Rochowska M., Skurzak H., Butruk E. Induction of ornithine decarboxylase in normal and protein kinase C-depleted human colon carcinoma cells. J. Physiol. Pharmacol., 43: 373-382, 1992.[Medline]
  43. Tasken K., Kvale D., Hansson V., Jahnsen T. Protein kinase C activation selectively increases mRNA levels for one of the regulatory subunits (RI{alpha}) of cAMP-dependent protein kinases in HT-29 cells. Biochem. Biophys. Res. Commun., 172: 409-414, 1990.[CrossRef][Medline]
  44. Kopp R., Mayer P., Pfeiffer A. Agonist-induced desensitization of cholinergically stimulated phosphoinositide breakdown is independent of endogenously activated protein kinase C in HT-29 human colon carcinoma cells. Biochem. J., 269: 73-78, 1990.[Medline]
  45. Rickard K. L., Gibson P. R., Young G. P., Phillips W. A. Activation of protein kinase C augments butyrate-induced differentiation and turnover in human colonic epithelial cells in vitro. Carcinogenesis (Lond.), 20: 977-984, 1999.[Abstract/Free Full Text]
  46. McBain J. A., Eastman A., Simmons D. L., Pettit G. R., Mueller G. C. Phorbol ester augments butyrate-induced apoptosis of colon cancer cells. Int. J. Cancer, 67: 715-723, 1996.[CrossRef][Medline]
  47. Propper D. J., Macaulay V., O’Byrne K. J., Braybrooke J. P., Wilner S. M., Ganesan T. S., Talbot D. C., Harris A. L. A Phase II study of bryostatin 1 in metastatic malignant melanoma. Br. J. Cancer, 78: 1337-1341, 1998.[Medline]
  48. Tozer R. G., Burdette-Radoux S., Belanger K. NCIC CTG randomized Phase II study of two schedules of bryostatin 1 (NSC339555) in patients with advanced malignant melanoma (IND.104). Proc. Am. Soc. Clin. Oncol., 18: 532a 1999.
  49. Bedikian A., Plager C., Papadopoulos O. Phase II trial of bryostatin-1 in patients with melanoma. Proc. Am. Soc. Clin. Oncol., 18: 532a 1999.
  50. Carr M. E., Jr., Carr S. L., Grant S. A sensitive platelet activation-based functional assay for the antileukemic agent bryostatin 1. Anticancer Drugs, 6: 384-391, 1995.[Medline]
  51. Khan P., McGown A. T., Dawson M. J., Jayson G., Prendiville J. A., Pettit G. R., Crowther D. High-performance liquid chromatographic assay for the novel antitumor drug, bryostatin-1, incorporating a serum extraction technique. J. Chromatogr. B Biomed. Sci. Appl., 709: 113-117, 1998.[CrossRef][Medline]
  52. Elgie A. W., Sargent J. M., Alton P., Peters G. J., Noordhuis P., Williamson C. J., Taylor C. G. Modulation of resistance to ara-C by bryostatin in fresh blast cells from patients with AML. Leuk. Res., 22: 373-378, 1998.[CrossRef][Medline]
  53. Freemerman A. J., Vrana J. A., Tombes R. M., Jiang H., Chelleppan S. P., Fischer P. B., Grant S. Effects of antisense p21 (WAF1/CIP1/MDA6) expression on the induction of differentiation and drug-mediated apoptosis in human myeloid leukemia cells (HL-60). Leukemia (Baltimore), 11: 504-513, 1997.[CrossRef][Medline]
  54. Philip P. A., Li Y., Alonso M. Sensitization of human breast cancer cells to gemcitabine by bryostatin 1. Proc. Am. Assoc. Cancer Res., 40: 5 1999.
  55. Kaubisch A., Kelsen D. P., Saltz L., Kemeny N., O’Reilly E., Ilson D., Endres S., Barazzuol J., Schwartz G. K. A Phase I trial of weekly sequential bryostatin-1 (BRYO) and paclitaxel in patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol., 18: 166a 1999.
  56. Rosenthal M. A., Oratz R., Liebes L., Cahr M. H., Muggia F. M. Phase I study of bryostatin-1 (NSC 339555) and cisplatin in advanced malignancies. Proc. Am. Soc. Clin. Oncol., 18: 227a 1999.



This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
B. F. El-Rayes, S. Gadgeel, A. F. Shields, S. Manza, P. Lorusso, and P. A. Philip
Phase I Study of Bryostatin 1 and Gemcitabine
Clin. Cancer Res., December 1, 2006; 12(23): 7059 - 7062.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. H. Choi, T. Hyman, and P. M. Blumberg
Differential Effect of Bryostatin 1 and Phorbol 12-Myristate 13-Acetate on HOP-92 Cell Proliferation Is Mediated by Down-regulation of Protein Kinase C{delta}.
Cancer Res., July 15, 2006; 66(14): 7261 - 7269.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
E. Diaz-Rubio
New Chemotherapeutic Advances in Pancreatic, Colorectal, and Gastric Cancers
Oncologist, June 1, 2004; 9(3): 282 - 294.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. K. Strair, D. Schaar, L. Goodell, J. Aisner, K.-V. Chin, J. Eid, R. Senzon, X. X. Cui, Z. T. Han, B. Knox, et al.
Administration of a Phorbol Ester to Patients with Hematological Malignancies: Preliminary Results from a Phase I Clinical Trial of 12-O-Tetradecanoylphorbol-13-acetate
Clin. Cancer Res., August 1, 2002; 8(8): 2512 - 2518.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zonder, J. A.
Right arrow Articles by Philip, P. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zonder, J. A.
Right arrow Articles by Philip, P. A.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online